USPTO-FDA Collaboration: Stakeholders Advocate Action From PTAB Proceedings To Examiner Resources

 
• By Brenda Sandburg

AUTM advocates reform or elimination of inter partes review, DOJ warns of antitrust liability from misrepresentation, and AAM recommends modifying system for measuring productivity of patent examiners.

USPTO FDA patent
USPTO and FDA get public input on their collaboration to bolster the reliability of patents • Source: Nielsen Hobbs; Pink Sheet|Shutterstock image

More from Market Access

More from Pink Sheet